COVID-19 Impacts: Post-Traumatic Stress Disorder (PTSD) Therapeutics Market will Accelerate at a CAGR of Over 9% through 2020-2024 | Rising Prevalence of PTSD to Boost Growth | Technavio

Technavio has announced its latest market research report titled Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024 (Graphic: Business Wire)

LONDON--()--Technavio has been monitoring the post-traumatic stress disorder (PTSD) therapeutics market and it is poised to grow by USD 909.86 million during 2020-2024, progressing at a CAGR of over 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please request Free Sample Report on Covid-19 Impact

Frequently Asked Questions-

  • At what CAGR is the market projected to grow during the forecast period 2020-2024?
  • Growing at a CAGR of over 9%, the market growth will accelerate during the forecast period of 2020-2024.
  • What is the key factor driving the market?
  • Rising prevalence of PTSD is one of the key factors driving market growth.
  • What are the top players in the market?
  • AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG, and Pfizer Inc. are some of the major market participants.
  • Which region is expected to hold the highest market share in the market?
  • North America
  • What is the major trend of the market?
  • Emerging therapies for PTSD treatment are a major growth factor for the market.

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG, and Pfizer Inc. are some of the major market participants. The rising prevalence of PTSD will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in fast-growing segments, while maintaining their position in the slow-growing segments.

Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024: Segmentation

Post-Traumatic Stress Disorder (PTSD) Therapeutics Market is segmented as below:

  • Product
    • Antidepressants
    • Anxiolytics
    • Others
  • Geographic
    • North America
    • APAC
    • Europe
    • South America
    • MEA

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40905

Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our post-traumatic stress disorder (PTSD) therapeutics market report covers the following areas:

  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Market size
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Market trends
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Market analysis

This study identifies emerging therapies for PTSD treatment as one of the prime reasons driving the post-traumatic stress disorder (PTSD) therapeutics market growth during the next few years.

Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the post-traumatic stress disorder (PTSD) therapeutics market, including some of the vendors such as AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG, and Pfizer Inc. Backed with competitive intelligence and benchmarking, our research reports on the post-traumatic stress disorder (PTSD) therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024: Key Highlights

  • CAGR of the market during the forecast period 2020-2024
  • Detailed information on factors that will assist post-traumatic stress disorder (PTSD) therapeutics market growth during the next five years
  • Estimation of the post-traumatic stress disorder (PTSD) therapeutics market size and its contribution to the parent market
  • Predictions on upcoming trends and changes in consumer behavior
  • The growth of the post-traumatic stress disorder (PTSD) therapeutics market
  • Analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of post-traumatic stress disorder (PTSD) therapeutics market vendors

Table of Contents:

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product placement
  • Antidepressants - Market size and forecast 2019-2024
  • Anxiolytics - Market size and forecast 2019-2024
  • Other PTSD therapeutics - Market size and forecast 2019-2024
  • Market opportunity by Product

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • Azevan Pharmaceuticals Inc.
  • Bionomics Ltd.
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • H. Lundbeck AS
  • Mylan NV
  • Neurocrine Biosciences Inc.
  • Novartis International AG
  • Pfizer Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Release Summary

The Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market will grow by USD 909.86 mn during 2020-2024

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/